Pro Medicus Ltd (ASX: PME) shares are sliding again on Tuesday, adding to a weak start to the year.
The healthcare imaging software stock is down 1.15% to $140.59 in afternoon trade. That leaves it roughly 36% lower in 2026 so far.
That is a significant shift for a stock that has historically traded at a premium. It also raises questions about how the market is now pricing the business.
With attention now turning to whether the sell-off has gone too far, the key question is what happens from here.
Image source: Getty Images
A high-quality business, but priced for growth
Pro Medicus operates in a niche corner of healthcare technology, supplying imaging software to hospitals and diagnostic providers.
Its Visage platform allows clinicians to process and interpret medical images quickly, which has helped it build a strong position in large hospital networks, particularly in the United States.
The business model is built around long-term contracts, high margins, and deep integration into hospital systems. Once installed, switching costs are high, which supports recurring revenue and strong visibility over future earnings.
That structure has underpinned years of consistent growth. Its interim results showed revenue and earnings continuing to rise, supported by a growing base of contracted work.
More recently, contract momentum has remained strong. Pro Medicus has secured roughly $100 million in wins and renewals since February, often at higher pricing, with cardiology-related upsell starting to gain traction.
Why the share price has pulled back
The weakness in the share price has been driven more by sentiment than operations.
High-growth healthcare and tech stocks have faced a broad de-rating, and Pro Medicus has not been immune. With a price-to-earnings (P/E) ratio still sitting above 60, the stock remains sensitive to changes in market expectations.
That has been reflected in broker updates.
Morgans recently retained its 'buy' rating but reduced its price target to $210. The broker noted it has updated its model to reflect more achievable growth assumptions, staging implementation revenue more conservatively and marking foreign exchange to spot.
Even with those changes, it said the business itself remains strong, and long-term demand is still there.
Bell Potter has taken a similar view. It maintained a positive stance while trimming its target price to $226, still implying material upside from current levels.
What investors are watching now
At current levels, the focus is on delivery.
Pro Medicus continues to win new contracts and expand within existing customers, which is central to its growth outlook. The pace of those wins, and how quickly they convert into revenue, will be closely watched.
At the same time, valuation remains a key factor. Even after the recent fall, the stock still trades at a premium to most of the ASX.
That leaves less room for disappointment if growth slows.
Foolish takeaway
Pro Medicus remains a high-quality business with strong margins and recurring revenue.
The share price fall appears tied more to valuation than any clear change in the business.
And broker support is still there, even with lower price targets.
The recent pullback could be an opportunity for long-term investors if the company continues to grow as expected.
